drugset / Trial / NCT00023374
TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance
Completed
98 enrolled
Centers for Disease Control and Prevention
US Department of Veterans Affairs · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a prospective, open-label, nonrandomized trial using a largely-intermittent, six-month tuberculosis treatment regimen among patients who will not receive isoniazid due to the presence of initial isoniazid resistance or intolerance. Subjects are enrolled after resistance or intolerance to isoniazid has been documented, and are treated for a total of six months (nine months if baseline chest x-ray shows cavitation and 2-month sputum culture is positive) with twice weekly or thrice weekly rifampin, ethambutol, and pyrazinamide.
Timeline
- Start
- 2000-08
- Primary completion
- 2006-12
- Completion
- 2010-12
Publications
- Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, Goldberg SV; Tuberculosis Trials Consortium. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. Int J Tuberc Lung Dis. 2014 May;18(5):571-80. doi: 10.5588/ijtld.13.0304.
- Funck-Jensen KL, Dalsgaard J, Grove EL, Hvas AM, Kristensen SD. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets. 2013;24(7):528-37. doi: 10.3109/09537104.2012.738838. Epub 2012 Dec 5.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ethambutol | Small molecule | — | — |
| Subject | Pyrazinamide | Small molecule | — | — |
| Subject | Rifampin | Small molecule | — | — |